Loading
A 3,689-patient study showing that 36.6 percent of triple-negative tumours are HER2-low, that in triple-negative disease HER2-low tumours are biologically no different from HER2-zero ones, and that pathologists agree poorly on the score; the label matters only because a drug now depends on it.
Schettini, Chic, Brasó-Maristany, Paré and colleagues collected retrospective clinicopathological and PAM50 data from 3,689 patients with HER2-negative breast cancer. HER2-low (immunohistochemistry 1+ or 2+ without ERBB2 amplification) was more common in hormone receptor-positive disease (65.4 percent) than triple-negative disease (36.6 percent). Within hormone receptor-positive disease ERBB2 and luminal genes were more expressed in HER2-low than HER2 0 tumours, whereas in triple-negative disease no gene was differentially expressed by HER2 level; within HER2-low, ERBB2 levels were higher in hormone receptor-positive than triple-negative tumours; HER2-low was not associated with overall survival in either group; and reproducibility of the HER2-low call among pathologists was suboptimal.
HER2-low is a drug eligibility label, not a biological subtype, in triple-negative disease; because a third of patients qualify for trastuzumab deruxtecan on a score pathologists disagree about, re-scoring and digital assistance for HER2 0 versus 1+ is a practical gap.
Shares Immunohistochemistry (IHC), Digital pathology & AI, Biomarkers are not validated or standardised, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem and the tag tnbc-evidence.
Shares DESTINY-Breast04, DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group, HER2-low and HER2-ultralow metastatic breast cancer, HER2-low and HER2-ultralow and the tag tnbc-evidence.
Shares PAM50 / intrinsic subtypes, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag tnbc-evidence.
Shares Digital pathology & AI, Biomarkers are not validated or standardised, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares PAM50 / intrinsic subtypes, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag tnbc-evidence.
Shares Immunohistochemistry (IHC), Digital pathology & AI, Biomarkers are not validated or standardised, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem and the tag tnbc-evidence.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, HER2, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares PAM50 / intrinsic subtypes, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.